Method for determining human plasma antiviral drug concentration

An antiviral drug, human plasma technology, applied in the field of medical testing, can solve the problems of unsuitable for conventional treatment drug concentration monitoring, cumbersome and time-consuming operation, high analysis cost, and achieve the effects of low cost, improved detection sensitivity, and less plasma consumption.

Inactive Publication Date: 2010-01-13
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, in medical testing, there are domestic reports on methods for determining the concentration of relevant antiviral drugs in human plasma, but the method has various defects such as low sensitivity, cumbersome operation, time-consuming, low efficiency, and high analysis cost, and is not suitable for routine therapeutic drug concentration monitoring. ; There is no report on the simultaneous determination of the concentration of ACV, GCV and PCV in human plasma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for determining human plasma antiviral drug concentration
  • Method for determining human plasma antiviral drug concentration
  • Method for determining human plasma antiviral drug concentration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Chromatographic conditions:

[0030] HPLC system: Diamonsil C column 18 (200mm×4.6mm, 5μm), the mobile phase adopts gradient elution, 0~7min is 0.08%TFA-methanol (96:4, V / V), 7.01~10.0min is 0.08%TFA-methanol (40:60, V / V), 0.08% TFA-methanol (96:4, V / V) for 10.01~12.5min, flow rate 1.5mL·min -1 Column temperature 25℃; fluorescence excitation wavelength 260±1nm, emission wavelength 380±1nm.

[0031] Pretreatment of plasma samples:

[0032] Precisely draw 200μL of plasma into a 1.5mL centrifuge tube, add 50μL of 7% perchloric acid solution containing internal standard guanylic acid, vortex and shake for 30s, centrifuge for 15min (10000×g, 4℃), take 40μL of supernatant into The internal standard method is quantified by peak area.

[0033] Specificity:

[0034] Take blank plasma from 10 subjects who have not taken ACV, GCV, and PCV from different sources, and measure them according to the above-mentioned sample pretreatment and measurement methods. The results show that no endogeno...

Embodiment 2

[0042] Chromatographic conditions:

[0043] HPLC system: Diamonsil C column 18 (200mm×4.6mm, 5μm), the mobile phase adopts gradient elution, 0~7min is 0.1%TFA-methanol (96:4, V / V), 7.01~10.0min is 0.1%TFA-methanol (40:60, V / V), 0.1% TFA-methanol (96:4, V / V) for 10.01~12.5min, flow rate 1.5mL·min -1 Column temperature 25℃; fluorescence excitation wavelength 260±1nm, emission wavelength 380±1nm.

[0044] Pretreatment of plasma samples:

[0045] Precisely draw 200μL of plasma into a 1.5mL centrifuge tube, add 25μL of 20% perchloric acid solution containing internal standard guanylic acid, vortex for 30s, centrifuge for 10min (12000×g, 4℃), take 40μL of supernatant for injection , The internal standard method is quantified by peak area.

[0046] Specificity:

[0047] The blank plasma of 10 subjects who did not take ACV, GCV and PCV were collected from different sources and measured according to the above-mentioned sample pretreatment and measurement methods. No plasma endogenous substance...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
linear rangeaaaaaaaaaa
Login to view more

Abstract

The invention belongs to medical detection field, relates to an analysis detection method of drug in the body of a person, and specifically relates to the method that the densities of antiviral drugs in blood plasma of the person such as acyclovir, ganciclovir and penciclovir can be detected at the same time. The method in the invention is characterized in that pilot sample is pretreated; as acyclovir, ganciclovir and penciclovir have the character of strong fluorescence absorption, acyclovir, ganciclovir and penciclovir can be separated from each other in an acidity flowing phase chromatographic column and be detected by a fluorescence detector. The method in the invention has the advantages of little sample, simple, swift and sensitive pretreatment, short analysis period and low cost; furthermore, the invention doesn't need expensive equipment and reagent and is suitable for the detection of clinical conventional blood drug density of acyclovir, ganciclovir and penciclovir.

Description

Technical field [0001] The invention belongs to the field of medical testing, and relates to a method for analyzing and measuring drugs in the body, in particular to a method for determining the concentration of antiviral drugs in human plasma. Background technique [0002] At present, there are several antiviral drugs clinically used to treat viral diseases. Acyclovir (ACV), Ganciclovir (Ganciclovir, GCV) and Penciclovir (Penciclovir, PCV) are currently commonly used clinically Nucleoside antiviral drugs. Among them, ACV and GCV are the most important anti-cytomegalovirus drugs. PCV mainly has a strong inhibitory effect on type I and II herpes simplex virus, varicella-zoster virus and hepatitis B virus. When PCV is used in combination with ACV or GCV, the clinical efficacy is significantly enhanced. Because the pharmacokinetics of the three drugs vary greatly among individuals, combined medications are common, and liver and kidney function abnormalities can cause changes in t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N30/02G01N30/06G01N30/74G01N21/64
Inventor 道毅俊焦正钟明康
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap